Castle Biosciences, Inc. (CSTL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$32.91+0.80%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Castle Biosciences raised 2026 revenue guidance to $345-355 million. Sales grew about 10% last year. The company aims to improve its operating income and net income. It has a strong product in skin cancer diagnostics.
The company is still losing money with negative net income. Operating losses worsened from -$6.8M to -$18.4M recently. Revenue growth may slow or miss targets. Costs remain a big challenge.
The price is about 41% below our fair value near $41. Analysts expect about 10% revenue growth. Our view aligns with this but sees risk in profit improvement.
Breaks if: Net loss worsens beyond -$14.52 million over next year
Breaks if: Operating loss worsens beyond -$18.41 million over next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story, as CSTL aims to improve its financial performance after recent losses. The current thesis state reflects a cautious optimism, with management making strides in revenue growth and operational improvements.
The market appears to have priced in a low expectations gap, indicating that investors are not overly optimistic about CSTL's near-term performance. Valuation is considered cheap compared to peers, but the fundamentals suggest a need for caution.
Management is focused on increasing revenue guidance and achieving positive Adjusted EBITDA, which shows a commitment to operational improvement. However, the company remains loss-making, and recent financial performance has been neutral, indicating potential volatility.
The long-term thesis hinges on CSTL's ability to maintain revenue growth and improve profitability while navigating external pressures like economic conditions and sector performance. Key factors include the performance of sector bellwethers and the company's ability to meet its guidance without cutting expectations.
The most important moves since the prior daily snapshot.
Valuation fell by 10.9 points (from 63.5 to 52.6).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Annual revenue falls below $345 million in 2026
Castle Biosciences has raised its 2026 revenue guidance to a range of $345-355 million.
In the next 1 to 3 years, CSTL's trajectory will depend on its operational execution and external market conditions. Not investment advice.